Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Jun
17
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
Jun
12
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Jun
11
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
Apr
03
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
Mar
19
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
Mar
12
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
Mar
07
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
Mar
07
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
Feb
27
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth